These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1447706)

  • 41. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.
    Gross DM; Sweet CS; Ulm EH; Backlund EP; Morris AA; Weitz D; Bohn DL; Wenger HC; Vassil TC; Stone CA
    J Pharmacol Exp Ther; 1981 Mar; 216(3):552-7. PubMed ID: 6259322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bioequivalence of a new liquid formulation of benazepril compared with the reference tablet product.
    Kelers K; Devi JL; Anderson GA; Zahra P; Vine JH; Whittem T
    Aust Vet J; 2013 Aug; 91(8):312-9. PubMed ID: 23889096
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of the new thyrotropin releasing hormone analogue montirelin hydrate. 1st communication: plasma concentrations, metabolism and excretion after a single intravenous administration to rats, dogs and monkeys.
    Sugimoto T; Hayashi T; Okita A; Morino A
    Arzneimittelforschung; 1996 Feb; 46(2):106-13. PubMed ID: 8720298
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Angiotensin converting enzyme inhibitory activity of SCH 33844 (spirapril) in rats, dogs and monkeys.
    Sybertz EJ; Baum T; Ahn HS; Desiderio DM; Pula KK; Tedesco R; Washington P; Sabin C; Smith E; Becker F
    Arch Int Pharmacodyn Ther; 1987 Apr; 286(2):216-29. PubMed ID: 3036028
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic/pharmacodynamic modeling of benazepril and benazeprilat after administration of intravenous and oral doses of benazepril in healthy horses.
    Serrano-Rodríguez JM; Gómez-Díez M; Esgueva M; Castejón-Riber C; Mena-Bravo A; Priego-Capote F; Ayala N; Caballero JMS; Muñoz A
    Res Vet Sci; 2017 Oct; 114():117-122. PubMed ID: 28371693
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel prodrug approach for tertiary amines. 3. In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs.
    Krise JP; Charman WN; Charman SA; Stella VJ
    J Pharm Sci; 1999 Sep; 88(9):928-32. PubMed ID: 10479356
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans.
    Suzuki H; Kawaratani T; Shioya H; Uji Y; Saruta T
    Biopharm Drug Dispos; 1993 Jan; 14(1):41-50. PubMed ID: 8427943
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites.
    Lefebvre HP; Laroute V; Concordet D; Toutain PL
    J Vet Intern Med; 1999; 13(1):21-7. PubMed ID: 10052059
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration.
    Okuyama Y; Momota K; Morino A
    Arzneimittelforschung; 1997 Mar; 47(3):276-84. PubMed ID: 9105546
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An angiotensin converting enzyme inhibitor, benazepril can be transformed to an active metabolite, benazeprilat, by the liver of dogs with ascitic pulmonary heartworm disease.
    Kitagawa H; Ohba Y; Kuwahara Y; Ohne R; Kondo M; Nakano M; Sasaki Y; Kitoh K
    J Vet Med Sci; 2003 Jun; 65(6):701-6. PubMed ID: 12867730
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of NS-49, a phenethylamine class alpha 1A-adrenoceptor agonist. 2nd communication: Absorption and excretion in rabbits, dogs and monkeys after a single administration of 14C-NS-49.
    Mukai H; Watanabe S; Morino A
    Arzneimittelforschung; 1999 Jun; 49(6):527-32. PubMed ID: 10417870
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Absorption of ACE inhibitors from small intestine and colon.
    Kim JS; Oberle RL; Krummel DA; Dressman JB; Fleisher D
    J Pharm Sci; 1994 Sep; 83(9):1350-6. PubMed ID: 7830254
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys.
    de Miranda P; Burnette TC
    Drug Metab Dispos; 1994; 22(1):55-9. PubMed ID: 8149890
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys.
    Maeshiba Y; Kiyota Y; Yamashita K; Yoshimura Y; Motohashi M; Tanayama S
    Arzneimittelforschung; 1997 Jan; 47(1):29-35. PubMed ID: 9037440
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The disposition of prasugrel, a novel thienopyridine, in humans.
    Farid NA; Smith RL; Gillespie TA; Rash TJ; Blair PE; Kurihara A; Goldberg MJ
    Drug Metab Dispos; 2007 Jul; 35(7):1096-104. PubMed ID: 17403916
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys.
    Mattiuz E; Franklin R; Gillespie T; Murphy A; Bernstein J; Chiu A; Hotten T; Kassahun K
    Drug Metab Dispos; 1997 May; 25(5):573-83. PubMed ID: 9152596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. No clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240.
    Martin NE; Howell SR; Martin LL; Cirillo I; Barrett JS
    J Clin Pharmacol; 2004 Apr; 44(4):379-87. PubMed ID: 15051745
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biliary excretion and conjugation of diacid angiotensin-converting enzyme inhibitors.
    Drummer OH; Nicolaci J; Iakovidis D
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1202-6. PubMed ID: 2319468
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.
    Blech S; Ebner T; Ludwig-Schwellinger E; Stangier J; Roth W
    Drug Metab Dispos; 2008 Feb; 36(2):386-99. PubMed ID: 18006647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.